GB2564175B - Anti-RSV monoclonal antibody formulation - Google Patents

Anti-RSV monoclonal antibody formulation Download PDF

Info

Publication number
GB2564175B
GB2564175B GB1802974.4A GB201802974A GB2564175B GB 2564175 B GB2564175 B GB 2564175B GB 201802974 A GB201802974 A GB 201802974A GB 2564175 B GB2564175 B GB 2564175B
Authority
GB
United Kingdom
Prior art keywords
monoclonal antibody
antibody formulation
rsv monoclonal
rsv
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
GB1802974.4A
Other languages
English (en)
Other versions
GB201802974D0 (en
GB2564175A (en
Inventor
Lobo Brian
Goldberg Deborah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune Ltd filed Critical MedImmune Ltd
Publication of GB201802974D0 publication Critical patent/GB201802974D0/en
Publication of GB2564175A publication Critical patent/GB2564175A/en
Application granted granted Critical
Publication of GB2564175B publication Critical patent/GB2564175B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GB1802974.4A 2017-03-01 2018-02-23 Anti-RSV monoclonal antibody formulation Active GB2564175B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762465379P 2017-03-01 2017-03-01

Publications (3)

Publication Number Publication Date
GB201802974D0 GB201802974D0 (en) 2018-04-11
GB2564175A GB2564175A (en) 2019-01-09
GB2564175B true GB2564175B (en) 2021-12-08

Family

ID=61903153

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1802974.4A Active GB2564175B (en) 2017-03-01 2018-02-23 Anti-RSV monoclonal antibody formulation

Country Status (24)

Country Link
US (4) US10774133B2 (enExample)
EP (1) EP3589648A4 (enExample)
JP (2) JP7046088B2 (enExample)
KR (2) KR102359181B1 (enExample)
CN (3) CN110418803B (enExample)
AR (1) AR111083A1 (enExample)
AU (2) AU2018227502B2 (enExample)
BR (1) BR112019017755A2 (enExample)
CA (1) CA3051864A1 (enExample)
CL (1) CL2019002478A1 (enExample)
CO (1) CO2019009034A2 (enExample)
CR (1) CR20190400A (enExample)
EA (1) EA201991701A1 (enExample)
EC (1) ECSP19062769A (enExample)
GB (1) GB2564175B (enExample)
IL (2) IL312499A (enExample)
MX (1) MX2019010408A (enExample)
MY (1) MY206022A (enExample)
PH (1) PH12019501979A1 (enExample)
SG (1) SG11201906853QA (enExample)
TW (3) TWI911431B (enExample)
UA (1) UA128450C2 (enExample)
WO (1) WO2018160722A1 (enExample)
ZA (1) ZA202006797B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
RS60387B1 (sr) 2014-01-15 2020-07-31 Medimmune Llc Rsv-specifična antitela i njihovi funkcionalni delovi
EP3383435A4 (en) * 2015-11-30 2019-07-10 Medimmune, LLC OPTIMIZED RATES OF AMINO ACIDS AND SUGARS AS AMORPHOUS STABILIZING COMPOUNDS IN PHARMACEUTICAL COMPOSITIONS HAVING HIGH CONCENTRATIONS IN PROTEIN-BASED THERAPEUTICS
TWI911431B (zh) 2017-03-01 2026-01-11 英商梅迪繆思有限公司 抗rsv單株抗體配製物
JP2020509025A (ja) * 2017-03-01 2020-03-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ モノクローナル抗体製剤
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
CN110913906A (zh) 2017-05-02 2020-03-24 默沙东公司 抗lag3抗体的制剂和抗lag3抗体与抗pd-1抗体的共制剂
MX2021004356A (es) 2018-10-18 2021-05-31 Merck Sharp & Dohme Llc Formulaciones de anticuerpos anti-rsv y metodos de uso de las mismas.
MA54089A (fr) 2018-10-31 2022-02-09 Merck Sharp & Dohme Anticorps anti-pd-1 humain et procédés d'utilisation associés
JP7503056B6 (ja) 2018-11-07 2024-07-16 メルク・シャープ・アンド・ドーム・エルエルシー 抗ｌａｇ３抗体および抗ｐｄ－１抗体の共－製剤
PE20212185A1 (es) 2019-02-18 2021-11-11 Lilly Co Eli Formulacion de anticuerpos terapeuticos
EP3956351A1 (en) * 2019-04-18 2022-02-23 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Biological and synthetic molecules inhibiting respiratory syncytial virus infection
US12024553B2 (en) 2019-04-30 2024-07-02 Medimmune Limited Dosage regimens for and compositions including anti-RSV antibodies
WO2021195418A1 (en) 2020-03-26 2021-09-30 Vanderbilt University Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
IL300245A (en) * 2020-07-31 2023-03-01 Alamab Therapeutics Inc Anti-connexin antibody formulations
CN115960214A (zh) * 2021-10-12 2023-04-14 中国科学院分子细胞科学卓越创新中心 中和呼吸道合胞病毒的全人抗体的设计及应用
TW202342510A (zh) 2022-02-18 2023-11-01 英商Ｒｑ生物科技有限公司 抗體
CN116987183B (zh) * 2022-07-22 2024-10-15 北京智仁美博生物科技有限公司 抗呼吸道合胞病毒中和性抗体及其用途
EP4588936A4 (en) * 2022-12-08 2026-08-12 Changchun Bcht Biotechnology Co ANTIBODIES THAT BIND SPECIFICALLY TO VRS
CN121846262A (zh) * 2026-01-05 2026-04-14 上海生物制品研究所有限责任公司 抗呼吸道合胞病毒单克隆抗体制剂

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003039485A2 (en) * 2001-11-08 2003-05-15 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
WO2003106644A2 (en) * 2002-06-14 2003-12-24 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (rsv) antibody formulations
WO2004091658A1 (en) * 2003-04-04 2004-10-28 Genentech, Inc. High concentration antibody and protein formulations
EP2238985A1 (en) * 2007-12-27 2010-10-13 Chugai Seiyaku Kabushiki Kaisha High concentration antibody-containing liquid formulation
WO2013148686A2 (en) * 2012-03-26 2013-10-03 Sanofi Stable igg4 binding agent formulations
WO2014036076A1 (en) * 2012-08-31 2014-03-06 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
WO2016059512A1 (en) * 2014-10-18 2016-04-21 Pfizer Inc. Anti-il-7r antibody compositions
WO2018160722A1 (en) * 2017-03-01 2018-09-07 Medimmune Limited Anti-rsv monoclonal antibody formulation
WO2018158332A1 (en) * 2017-03-01 2018-09-07 Medimmune Limited Formulations of monoclonal antibodies

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5811524A (en) 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
ES2148799T3 (es) 1995-09-18 2000-10-16 Intracel Corp Anticuerpos monoclonales neutralizantes contra virus sincitial respiratorio.
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
US7132100B2 (en) * 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
AU2013201261B2 (en) * 2002-06-14 2016-06-23 Medimmune, Llc Stabilized liquid anti-RSV antibody formulations
TW200636064A (en) 2004-10-28 2006-10-16 Centocor Inc Anti-respiratory syncytial virus antibodies, antigens and uses thereof
AU2007223903B2 (en) * 2006-03-06 2013-09-05 Medimmune, Llc Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
BRPI0921424A2 (pt) 2008-11-05 2016-01-05 Merck Sharp & Dohme vírus sincicial respiratório atenuado, composição imunogênica, molécula de ácido nucléico, célula recombinante, método para produzir uma resposta imune protetiva em um paciente, e, uso de uma quantidade imunologicamente eficaz de um ou mais dos seguintes: um rsv atenuado, uma população de rsv atenuado e uma composição imunogênica.
WO2011017070A1 (en) * 2009-07-28 2011-02-10 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
WO2011043643A1 (en) * 2009-10-06 2011-04-14 Medimmune Ltd Rsv-specific binding molecule
CL2011003002A1 (es) 2011-11-25 2012-05-25 Univ Pontificia Catolica Chile Anticuerpo monoclonal o un fragmento del mismo que se une a la proteina m2-1 del virus respiratorio sincicial (vrs) humano; secuencias nucleotidicas; composicion farmaceutica; metodo de diagnostico de infeccion producida por vrs; kit; y uso de dicho anticuerpo para preparar un medicamento.
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
RS60056B1 (sr) 2013-02-01 2020-04-30 Medimmune Llc Epitopi f proteina respiratornog sincicijalnog virusa
RS60387B1 (sr) 2014-01-15 2020-07-31 Medimmune Llc Rsv-specifična antitela i njihovi funkcionalni delovi
CN107847580B (zh) 2015-07-07 2022-08-12 扬森疫苗与预防公司 针对rsv的疫苗
JO3555B1 (ar) 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
US12024553B2 (en) * 2019-04-30 2024-07-02 Medimmune Limited Dosage regimens for and compositions including anti-RSV antibodies

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003039485A2 (en) * 2001-11-08 2003-05-15 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
WO2003106644A2 (en) * 2002-06-14 2003-12-24 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (rsv) antibody formulations
WO2004091658A1 (en) * 2003-04-04 2004-10-28 Genentech, Inc. High concentration antibody and protein formulations
EP2238985A1 (en) * 2007-12-27 2010-10-13 Chugai Seiyaku Kabushiki Kaisha High concentration antibody-containing liquid formulation
WO2013148686A2 (en) * 2012-03-26 2013-10-03 Sanofi Stable igg4 binding agent formulations
WO2014036076A1 (en) * 2012-08-31 2014-03-06 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
WO2016059512A1 (en) * 2014-10-18 2016-04-21 Pfizer Inc. Anti-il-7r antibody compositions
WO2018160722A1 (en) * 2017-03-01 2018-09-07 Medimmune Limited Anti-rsv monoclonal antibody formulation
WO2018158332A1 (en) * 2017-03-01 2018-09-07 Medimmune Limited Formulations of monoclonal antibodies

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Antimicrobial Agents and Chemotherapy, Vol. 61, No. 3, 23 Feb. 2017, PM Griffin, et al., "Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults", page e01714 - 16 *
Molecular Pharmaceutics, Vol. 11, No. 6, Jun. 2014, Inoue Naoto et al., "Specific decrease in solution viscosity of antibodies by arginine for therapeutic formulations", pages 1889 - 1896. *

Also Published As

Publication number Publication date
CA3051864A1 (en) 2018-09-07
AU2022263564B2 (en) 2025-05-22
EP3589648A1 (en) 2020-01-08
CN116059343B (zh) 2026-06-02
CN117982637A (zh) 2024-05-07
AU2022263564A1 (en) 2022-12-15
KR102668158B1 (ko) 2024-05-23
KR20220020420A (ko) 2022-02-18
MY206022A (en) 2024-11-25
ECSP19062769A (es) 2019-09-30
CL2019002478A1 (es) 2020-01-24
CN116059343A (zh) 2023-05-05
GB201802974D0 (en) 2018-04-11
TWI761453B (zh) 2022-04-21
TW201840334A (zh) 2018-11-16
CO2019009034A2 (es) 2019-08-30
CN110418803A (zh) 2019-11-05
KR102359181B1 (ko) 2022-02-08
JP2020509031A (ja) 2020-03-26
KR20190125318A (ko) 2019-11-06
TWI911431B (zh) 2026-01-11
AR111083A1 (es) 2019-05-29
US20180251526A1 (en) 2018-09-06
IL268202B1 (en) 2024-06-01
AU2018227502B2 (en) 2022-08-11
IL312499A (en) 2024-07-01
US20200339667A1 (en) 2020-10-29
US10774133B2 (en) 2020-09-15
US11286294B2 (en) 2022-03-29
US20210317191A1 (en) 2021-10-14
US20230399383A1 (en) 2023-12-14
TWI926892B (zh) 2026-05-21
GB2564175A (en) 2019-01-09
NZ755790A (en) 2024-04-26
PH12019501979A1 (en) 2020-06-29
AU2018227502A1 (en) 2019-08-15
CR20190400A (es) 2019-12-03
SG11201906853QA (en) 2019-09-27
TW202615095A (zh) 2026-04-16
JP7446356B2 (ja) 2024-03-08
MX2019010408A (es) 2019-12-19
CN110418803B (zh) 2024-01-19
WO2018160722A1 (en) 2018-09-07
TW202228779A (zh) 2022-08-01
UA128450C2 (uk) 2024-07-17
IL268202A (en) 2019-09-26
US11667698B2 (en) 2023-06-06
JP2022095697A (ja) 2022-06-28
IL268202B2 (en) 2024-10-01
BR112019017755A2 (pt) 2020-04-07
EA201991701A1 (ru) 2020-03-04
EP3589648A4 (en) 2020-12-23
JP7046088B2 (ja) 2022-04-01
ZA202006797B (en) 2023-03-29

Similar Documents

Publication Publication Date Title
TWI926892B (zh) 抗ｒｓｖ單株抗體配製物
IL269499A (en) Stable antibody formulation
SG11202001368SA (en) Antigen-binding proteins tatrgeting shared antigens
ZA201900353B (en) Anti-pd-l1 antibodies
IL262295B1 (en) Antibodies against pd–l1
ZA202006263B (en) Antibody formulation
IL271416A (en) Bispecific antibody formulation
ZA201807167B (en) Humanized anti-il-1r3 antibodies
SG11202103064YA (en) Antibody formulation
SG10201912556VA (en) HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)
SG11202104300PA (en) Antibody formulation
IL268943A (en) Aqueous formulation of ANTI-PD-L1 antibody
IL273529A (en) Anti-PACAP antibody
IL267271A (en) Antibodies against il-5
ZA202006262B (en) Stable antibody formulation
HK40002161B (en) Anti-rsv monoclonal antibody formulation
GB201621907D0 (en) Antibody epitope
HK40020516A (en) Anti-rsv monoclonal antibody formulation
GB201511196D0 (en) Monoclonal antibodies
GB201709592D0 (en) Antibody
GB201620276D0 (en) Anti-AFB1 Fab antibody

Legal Events

Date Code Title Description
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40002161

Country of ref document: HK